Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Plurihormonal (TSH-GH-prolactin Secreting) PIT-1-Positive pituitary Macroadenoma/Pituitary Neuroendocrine Tumor (PitNET) Associated with Graves’ Disease: A Case Report

Author(s): Cesare Morgante*, Federica Guaraldi, Sofia Asioli, Diego Mazzatenta, Giampaolo Papi and Alfredo Pontecorvi

Volume 23, Issue 12, 2023

Published on: 23 June, 2023

Page: [1557 - 1561] Pages: 5

DOI: 10.2174/1871530323666230623161631

Price: $65

Abstract

Background: Differential diagnosis of primary and secondary hyperthyroidism can be challenging. Moreover, although extremely rare, the two conditions can coexist.

Case Presentation: A 58-year-old woman presented with symptoms of thyrotoxicosis, gradual changes in face shape, headache and progressive enlargement of hands and feet in the last year. When she was 46 years old, she was diagnosed with Graves’ disease, and treated with 4-year methimazole therapy. Since 2016, a progressive increase of free-T4 and free-T3 with normal-TSH and positive TrAb was noticed.

Results: At biochemical examination, fT3 was 5.3pg/ml (n. v. 2.5 - 3.9 pg/ml), fT4 was 20.6 pg/ml (n.v 6-12 pg/ml), IGF1 was 698 ng/ml (57 – 240 ng/ml*), GH (basally and after OGTT), and prolactin were significantly increased; while TSH was 1.8 (n.v. 0.35-4.0 mcUI/ml). A pituitary MRI demonstrated a large sellar tumor with suprasellar extension. The patient underwent endoscopic transsphenoidal surgery. Histological examination revealed a plurihormonal (GH-PRLTSH- secreting) PIT-1-positive pituitary adenoma/pituitary neuroendocrine tumor (PitNET). At 3- month follow-up, the pituitary function was normal, and no residual tumor was detected at the MRI.

Conclusion: We report a rare case of Graves’ disease coexisting with a plurihormonal PIT-1-positive pituitary adenoma/PitNET.

Keywords: Plurihormonal Pit-1-positive-Pituitary Adenoma, TSH-secreting adenoma, GH-secreting adenoma, prolactinoma, Pituitary Neuroendocrine Tumor (PitNET), Graves’ disease.

« Previous Next »
Graphical Abstract

[1]
Ross, D.S.; Burch, H.B.; Cooper, D.S.; Greenlee, M.C.; Laurberg, P.; Maia, A.L.; Rivkees, S.A.; Samuels, M.; Sosa, J.A.; Stan, M.N.; Walter, M.A. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 2016, 26(10), 1343-1421.
[http://dx.doi.org/10.1089/thy.2016.0229] [PMID: 27521067]
[2]
2022 WHO classification of endocrine and neuroendocrine tumors. 2022. Available from: https://www.endocrinology.org/endocrinologist/147-spring-23/hot-topics/2022-who-classification-of-endocrine-and-neuroendocrine-tumors/
[3]
Beck-Peccoz, P.; Giavoli, C.; Lania, A.A. 2019 update on TSH-secreting pituitary adenomas. J. Endocrinol. Invest., 2019, 42(12), 1401-1406.
[http://dx.doi.org/10.1007/s40618-019-01066-x] [PMID: 31175617]
[4]
Beck-Peccoz, P.; Lania, A.; Beckers, A.; Chatterjee, K.; Wemeau, J.L. 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur. Thyroid J., 2013, 2(2), 76-82.
[http://dx.doi.org/10.1159/000351007] [PMID: 24783044]
[5]
Santos Mata, M.A.; Ariza Jimenez, A.B.; Macias Lopez, F.; de la Camara Moraño, C. Thyroid hormone resistance: Multicentrical case series study. Horm. Metab. Res., 2022, 54(2), 67-75.
[http://dx.doi.org/10.1055/a-1725-8533] [PMID: 35130567]
[6]
Frank, G.; Pasquini, E.; Farneti, G.; Mazzatenta, D.; Sciarretta, V.; Grasso, V.; Faustini, F.M. The endoscopic versus the traditional approach in pituitary surgery. Neuroendocrinology, 2006, 83(3-4), 240-248.
[http://dx.doi.org/10.1159/000095534] [PMID: 17047389]
[7]
Beck-Peccoz, P.; Brucker-Davis, F.; Persani, L.; Smallridge, R.C.; Weintraub, B.D. Thyrotropin-secreting pituitary tumors. Endocr. Rev., 1996, 17(6), 610-638.
[http://dx.doi.org/10.1210/edrv-17-6-610] [PMID: 8969971]
[8]
Villa, C.; Vasiljevic, A.; Jaffrain-Rea, M.L.; Ansorge, O.; Asioli, S.; Barresi, V.; Chinezu, L.; Gardiman, M.P.; Lania, A.; Lapshina, A.M.; Poliani, L.; Reiniger, L.; Righi, A.; Saeger, W.; Soukup, J.; Theodoropoulou, M.; Uccella, S.; Trouillas, J.; Roncaroli, F. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): A European Pituitary Pathology Group (EPPG) proposal. Virchows Arch., 2019, 475(6), 687-692.
[http://dx.doi.org/10.1007/s00428-019-02655-0] [PMID: 31578606]
[9]
Piantanida, E. Preoperative management in patients with Graves’ disease. Gland Surg., 2017, 6(5), 476-481.
[http://dx.doi.org/10.21037/gs.2017.05.09] [PMID: 29142837]
[10]
Sadoul, J.L.; Thyss, A.; Freychet, P. Invasive mixed growth hormone/prolactin secreting pituitary tumour: Complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal. Eur. J. Endocrinol., 1992, 126(2), 179-183.
[http://dx.doi.org/10.1530/acta.0.1260179] [PMID: 1543025]
[11]
Demura, R.; Demura, H.; Odagiri, E.; Shizume, K. A case of acromegaly associated with Graves’ disease. A possible role of endogenous TRH and an effect of bromocriptine on GH and TSH secretion. Endocrinol. Jpn., 1984, 31(6), 801-807.
[http://dx.doi.org/10.1507/endocrj1954.31.801] [PMID: 6442699]
[12]
Krieger, C.C.; Neumann, S.; Gershengorn, M.C. TSH/IGF1 receptor crosstalk: Mechanism and clinical implications. Pharmacol. Ther., 2020, 209, 107502.
[http://dx.doi.org/10.1016/j.pharmthera.2020.107502] [PMID: 32061922]
[13]
Krieger, C.C.; Neumann, S.; Place, R.F.; Marcus-Samuels, B.; Gershengorn, M.C. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves’ disease immunoglobins. J. Clin. Endocrinol. Metab., 2015, 100(3), 1071-1077.
[http://dx.doi.org/10.1210/jc.2014-3566] [PMID: 25485727]
[14]
Kahaly, G.J.; Douglas, R.S.; Holt, R.J.; Sile, S.; Smith, T.J. Teprotumumab for patients with active thyroid eye disease: A pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol., 2021, 9(6), 360-372.
[http://dx.doi.org/10.1016/S2213-8587(21)00056-5] [PMID: 33865501]
[15]
Bartalena, L.; Kahaly, G.J.; Baldeschi, L.; Dayan, C.M.; Eckstein, A.; Marcocci, C.; Marinò, M.; Vaidya, B.; Wiersinga, W.M. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur. J. Endocrinol., 2021, 185(4), G43-G67.
[http://dx.doi.org/10.1530/EJE-21-0479] [PMID: 34297684]
[16]
Marcocci, C.; Kahaly, G.J.; Krassas, G.E.; Bartalena, L.; Prummel, M.; Stahl, M.; Altea, M.A.; Nardi, M.; Pitz, S.; Boboridis, K.; Sivelli, P.; von Arx, G.; Mourits, M.P.; Baldeschi, L.; Bencivelli, W.; Wiersinga, W. Selenium and the course of mild Graves’ orbitopathy. N. Engl. J. Med., 2011, 364(20), 1920-1931.
[http://dx.doi.org/10.1056/NEJMoa1012985] [PMID: 21591944]
[17]
Arai, N.; Inaba, M.; Ichijyo, T.; Kagami, H.; Mine, Y. Thyrotropin-producing pituitary adenoma simultaneously existing with Graves’ disease: A case report. J. Med. Case Reports, 2017, 11(1), 9.
[http://dx.doi.org/10.1186/s13256-016-1172-4] [PMID: 28061802]
[18]
Guaraldi, F.; Gori, D.; Beccuti, G.; Prencipe, N.; Giordano, R.; Mints, Y.; Di Giacomo, V.S.; Berton, A.; Lorente, M.; Gasco, V.; Ghigo, E.; Salvatori, R.; Grottoli, S. Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up. J. Endocrinol. Invest., 2016, 39(11), 1277-1284.
[http://dx.doi.org/10.1007/s40618-016-0476-y] [PMID: 27153851]
[19]
Thakker, R.V. Multiple endocrine neoplasia type 1 (MEN1). Best Pract. Res. Clin. Endocrinol. Metab., 2010, 24(3), 355-370.
[http://dx.doi.org/10.1016/j.beem.2010.07.003] [PMID: 20833329]
[20]
Kamoun, M.; d’Herbomez, M.; Lemaire, C.; Fayard, A.; Desailloud, R.; Huglo, D.; Wemeau, J.L. Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and graves’ hyperthyroidism. Eur. Thyroid J., 2014, 3(1), 60-64.
[http://dx.doi.org/10.1159/000355386] [PMID: 24847468]
[21]
Fu, J.; Wu, A.; Wang, X.; Guan, H. Concurrent graves’ disease and tsh secreting pituitary adenoma presenting suppressed thyrotropin levels: a case report and review of the literature. Front. Endocrinol., 2020, 11, 523.
[http://dx.doi.org/10.3389/fendo.2020.00523] [PMID: 32849306]
[22]
Quinn, M.; Bashari, W.; Smith, D.; Gurnell, M.; Agha, A. A remarkable case of thyrotoxicosis initially caused by graves’ disease followed by a probable TSHoma – a case report. BMC Endocr. Disord., 2020, 20(1), 133.
[http://dx.doi.org/10.1186/s12902-020-00611-7] [PMID: 32854689]

Rights & Permissions Print Cite
Article Metrics
23
3
© 2024 Bentham Science Publishers | Privacy Policy